[go: up one dir, main page]

CA2500313A1 - Composition polymere et formes posologiques la comprenant - Google Patents

Composition polymere et formes posologiques la comprenant Download PDF

Info

Publication number
CA2500313A1
CA2500313A1 CA002500313A CA2500313A CA2500313A1 CA 2500313 A1 CA2500313 A1 CA 2500313A1 CA 002500313 A CA002500313 A CA 002500313A CA 2500313 A CA2500313 A CA 2500313A CA 2500313 A1 CA2500313 A1 CA 2500313A1
Authority
CA
Canada
Prior art keywords
molecular weight
water soluble
high molecular
composition
soluble polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002500313A
Other languages
English (en)
Other versions
CA2500313C (fr
Inventor
Jen-Chi Chen
Frank J. Bunick
Harry S. Sowden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/031129 external-priority patent/WO2003026630A1/fr
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2003/008960 external-priority patent/WO2004028514A1/fr
Publication of CA2500313A1 publication Critical patent/CA2500313A1/fr
Application granted granted Critical
Publication of CA2500313C publication Critical patent/CA2500313C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition comprenant d'une part un polymère hydrosoluble de masse moléculaire élevée dont le point de trouble se situe approximativement entre 20 ·C et 90 ·C, et d'autre part un polymère de gélification. Cette composition convient comme composant d'une forme posologique pharmaceutique, et notamment la coque d'une forme posologique. Cette forme posologique convient également comme matrice comestible, c'est-à-dire directement comme forme posologique pharmaceutique.
CA2500313A 2002-09-28 2003-03-21 Composition polymere et formes posologiques la comprenant Expired - Fee Related CA2500313C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
PCT/US2002/031129 WO2003026630A1 (fr) 2001-09-28 2002-09-28 Formes dosifiees presentant un noyau interne et une couche externe de formes differentes
USPCT/US02/31163 2002-09-28
USPCT/US02/31129 2002-09-28
PCT/US2002/031024 WO2003026625A1 (fr) 2001-09-28 2002-09-28 Formes pharmaceutiques a liberation modifiee
USPCT/US02/31062 2002-09-28
USPCT/US02/31117 2002-09-28
PCT/US2002/031163 WO2003026627A1 (fr) 2001-09-28 2002-09-28 Formes pharmaceutiques composites
PCT/US2002/031062 WO2003026626A2 (fr) 2001-09-28 2002-09-28 Forme pharmaceutique a liberation modifiee
USPCT/US02/31024 2002-09-28
PCT/US2002/031117 WO2003026629A2 (fr) 2001-09-28 2002-09-28 Formes de dosage a liberation modifiee
PCT/US2003/008960 WO2004028514A1 (fr) 2002-09-28 2003-03-21 Composition polymere et formes posologiques la comprenant

Publications (2)

Publication Number Publication Date
CA2500313A1 true CA2500313A1 (fr) 2004-04-08
CA2500313C CA2500313C (fr) 2011-06-07

Family

ID=34271652

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002500311A Abandoned CA2500311A1 (fr) 2002-09-28 2003-03-21 Formes de dosage a liberation modifiee
CA2500313A Expired - Fee Related CA2500313C (fr) 2002-09-28 2003-03-21 Composition polymere et formes posologiques la comprenant
CA002500312A Abandoned CA2500312A1 (fr) 2002-09-28 2003-03-21 Forme dosifiee a liberation modifiee

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002500311A Abandoned CA2500311A1 (fr) 2002-09-28 2003-03-21 Formes de dosage a liberation modifiee

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002500312A Abandoned CA2500312A1 (fr) 2002-09-28 2003-03-21 Forme dosifiee a liberation modifiee

Country Status (8)

Country Link
JP (3) JP2006517182A (fr)
CN (3) CN1700907A (fr)
AT (1) ATE444739T1 (fr)
AU (4) AU2003220472A1 (fr)
BR (5) BR0314547A (fr)
CA (3) CA2500311A1 (fr)
DE (2) DE60329614D1 (fr)
MX (1) MXPA05003283A (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470463C (fr) 2004-06-09 2012-09-18 Lornamead Brands, Inc. Produits blanchissants pour les dents et methodes de fabrication connexes
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2009153635A1 (fr) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg Forme pharmaceutique chrono-thérapeutique
KR20130010464A (ko) * 2010-03-23 2013-01-28 아스카 세이야쿠 가부시키가이샤 고형 제제
EP2729180B1 (fr) * 2011-07-08 2019-01-23 The University of North Carolina At Chapel Hill Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os
HK1203162A1 (en) * 2012-02-07 2015-10-23 麦克内尔-Ppc股份有限公司 Rapidly disintegrating coated tablets
EP2857006A4 (fr) * 2012-06-05 2015-12-30 Takeda Pharmaceutical Comprimé à enrobage sec
RU2017106028A (ru) * 2014-09-19 2018-10-22 Дзе Проктер Энд Гэмбл Компани Лекарственная форма фенилэфрина с пульсирующим высвобождением
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
EP3731821A1 (fr) * 2017-12-29 2020-11-04 Laxxon Medical AG Système d'administration de médicament
CA3226223A1 (fr) * 2021-07-30 2023-02-02 Jacob Pade Ramsoe Jacobsen Formes posologiques a retention gastrique de 5-hydroxytryptophane
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
CN115295864B (zh) * 2021-11-09 2023-08-11 深圳市德方创域新能源科技有限公司 正极补锂添加剂及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007470A1 (fr) * 1992-09-30 1994-04-14 Pfizer Inc. Article contenant un noyau et un revetement d'epaisseur non constante
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
AU2001250646A1 (en) * 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
CN1491105A (zh) * 2001-02-13 2004-04-21 新的改进释放的制剂

Also Published As

Publication number Publication date
CN1700908A (zh) 2005-11-23
MXPA05003283A (es) 2005-11-23
BR0314787A (pt) 2005-07-26
CN1684671A (zh) 2005-10-19
AU2003225944A1 (en) 2004-04-19
AU2003218359A1 (en) 2004-04-19
CN1700907A (zh) 2005-11-23
BR0314781A (pt) 2005-07-26
ATE444739T1 (de) 2009-10-15
AU2003220472A1 (en) 2004-04-19
JP2006517514A (ja) 2006-07-27
AU2003220466A1 (en) 2004-04-19
JP2006517182A (ja) 2006-07-20
CA2500312A1 (fr) 2004-04-08
BR0314547A (pt) 2005-08-09
BR0314777A (pt) 2005-07-26
BR0314804A (pt) 2005-08-02
DE60329614D1 (de) 2009-11-19
CA2500313C (fr) 2011-06-07
JP2006517183A (ja) 2006-07-20
CA2500311A1 (fr) 2004-04-08
DE60335270D1 (de) 2011-01-20

Similar Documents

Publication Publication Date Title
RU2005108576A (ru) Полимерная композиция и соднржащие ее лекарственные формы
CA2500313A1 (fr) Composition polymere et formes posologiques la comprenant
AU694261B2 (en) Modeling dough
CN103601416B (zh) 一种混凝土化学自修复微胶囊及其制备方法
JP5574369B2 (ja) 生物活性製剤の調製方法
CA2433186A1 (fr) Preparations pharmaceutiques a liberation retardee
JP2005538105A (ja) 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
IE882295L (en) Controlled release formulation
JPS60190725A (ja) 薬形用水性被覆剤分散液、耐胃液性に被覆された薬形の製法および耐胃液性薬形
CN103601415B (zh) 一种混凝土碱性调节微胶囊及其制备方法
US4931286A (en) High gloss cellulose tablet coating
CA2374020A1 (fr) Milieu de culture simple et son procede de preparation
WO2010139111A1 (fr) Forme posologique à libération prolongée
JP2002542276A5 (fr)
SE8300577L (sv) Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad ....
CA2390746A1 (fr) Composition pharmaceutique a bse de derives de quinolinone et methode pour sa production
HRP20190727T1 (hr) Formulacija odgođenog otpuštanja lijeka
CA2525542A1 (fr) Composition pharmaceutique a base de beraprost sodium a effet prolonge destinee a une administration orale
Osterwald Properties of film-formers and their use in aqueous systems
SI2328539T1 (en) A smooth coating composition having a high solids content per tablet
Abletshauser et al. Film coating of pellets with insoluble polymers obtained in situ crosslinking in the fluidized bed
CN104873457A (zh) 缓释剂型
US20040228916A1 (en) Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof
JPWO2018225770A1 (ja) シームレスカプセル皮膜用組成物及びシームレスカプセル
KR102149020B1 (ko) 높은 방습성을 가지는 필름코팅정

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190321